A Study to Evaluate the Effectiveness and Safety of RalinEpag for Improving Treatment Outcomes in PAH Patients

Overview

About this study

The purpose of this study is to demonstrate the effect of ralinepag the time to first adjudicated clinical worsening event in subjects with pulmonary arterial hypertension (PAH).Clinical worsening event is defined as 1 of the following: death, nonelective hospital admission of <24 hours due to worsening PAH or RHF, initiation of parenteral or inhaled therapy, disease progression, or unsatisfactory long term clinical response.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Each subject must meet ALL of the following inclusion criteria to be eligible for enrollment into the study:

1.    At least 18 years of age.
2.    Evidence of a personally signed and dated Informed Consent Form indicating that the subject has been informed of all pertinent aspects of the study prior to initiation of any study-related procedures.
3.    Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
4.    Primary diagnosis of symptomatic PAH classified by 1 of the following subgroups:
a.    Idiopathic pulmonary arterial hypertension (IPAH);
b.    Heritable pulmonary arterial hypertension (HPAH);
c.    Drugs or toxins induced PAH based on prior exposure to drugs, chemicals, or toxins, such as fenfluramine derivatives, other anorexigens, toxic rapeseed oil, or
L-    tryptophan.
d.    PAH associated with:
i.    CTD
ii.    Human immunodeficiency virus (HIV) infection
iii.    Congenital systemic-pulmonary shunt (must have undergone surgical correction at least 1 year prior to Screening and have no, or a clinically insignificant, shunt fraction [1.0 ≤ pulmonary-systemic flow ratio (QP/QS) ≤ 1.5]) in the opinion of the Investigator.
5.    Has had a right heart catheterization (RHC) performed at or within 3 years of Screening (RHC will be performed during Screening if not available) that is consistent with the diagnosis of PAH, meeting all of the following criteria:
a.    Pulmonary arterial pressure mean (PAPm) >20 mmHg (at rest)
b.    Pulmonary artery wedge pressure (PAWP) of ≤15 mmHg (if PAWP cannot be reliably attained, then left ventricular end diastolic pressure [LVEDP] ≤15 mmHg)
c.    Pulmonary vascular resistance (PVR) ≥3.00 Wood units (≥240 dynes/sec/cm5).
If more than 1 RHC was performed in the last 3 years prior to Screening, the most recent RHC that includes parameters sufficient to evaluate the above criteria must be used for this assessment.
6.    Has WHO/NYHA FC II to IV symptoms.
7.    If on PAH-specific background oral therapy, subject is on stable therapy with either an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 inhibitor
(PDE5-I) or a soluble guanylate cyclase (sGC) stimulator.  Subjects may be naïve to PAH-specific treatment; however, subjects must have access to locally available standard of care treatment in accordance with national guidelines.
a.    Stable is defined as no change in dose or regimen within 30 days prior to Baseline and for duration of the study.

b.    Subjects may be on either a PDE5-I or an sGC stimulator at a stable dose (but not both).
c.    If the subject’s disease-specific PAH therapy does not include a PDE5-I, the use of PDE5-I as needed for erectile dysfunction, up to 3 doses per week, is permitted. The subject should not have taken a dose within 48 hours of any Baseline or study related efficacy assessments.

8.    Has a 6MWD of ≥150 meters.
9.    If the subject is taking concomitant medications that may affect PAH (eg, calcium channel blockers, digoxin, or L-arginine supplementation), the subject must be on a stable dose for at least 30 days prior to the Baseline Visit and the dosage maintained throughout the study.
10.    Both male and female subjects agree to use a highly effective method of birth control throughout the entire study period from informed consent through to the 30-Day Follow-up Visit, if the possibility of conception exists.  Eligible male and female subjects must also agree not to participate in a conception process (ie, actively attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization) during the study and for 30 days after the last dose of IMP.

Exclusion Criteria

Subjects must not meet ANY of the following exclusion criteria to be eligible for enrollment into the study, unless otherwise indicated: 

1.    For subjects with known HIV-associated PAH, a cluster designation 4 (CD4+) T-cell count <200/mm3 within 90 days of Baseline.
2.    Subjects must not have 3 or more of the following left ventricular dysfunction risk factors:
    Body mass index (BMI) ≥30 kg/m2
    History of systemic hypertension
    Diabetes mellitus – any type
    Historical evidence of significant coronary disease established by any 1 of the following:
–    History of myocardial infarction or percutaneous coronary intervention or angiographic evidence of coronary artery disease (>50% stenosis in at least 1 coronary artery)
–    Positive stress test with imaging
–    Previous coronary artery bypass graft
–    Stable angina
    Any chronic atrial fibrillation

3.    Has evidence of more than mild lung disease on pulmonary function tests (PFTs) performed within 180 days prior to, or during Screening.  Subjects with any of the following criteria will be excluded:
a.    Forced expiratory volume in 1 second (FEV1) <60% (predicted); or Total lung capacity <60%

4.    Has evidence of thromboembolic disease as determined by ventilation-perfusion (V/Q) lung scan or local standard of care diagnostic evaluation at or after diagnosis of PAH.
5.    Current diagnosis of uncontrolled sleep apnea as defined by the Investigator.
6.    Male subjects with a corrected QT interval using Fridericia’s formula (QTcF)
>    450 msec and female subjects with QTcF >470 msec on electrocardiogram (ECG) measured at Screening or Baseline in subjects without evidence of intraventricular conduction delay (IVCD).  In presence of IVCD, subjects will be excluded if QTcF
>    500 msec for both males and females.
7.    Severe chronic liver disease (ie, Child-Pugh C), portal hypertension, cirrhosis or complications of cirrhosis/portal hypertension (eg, history of variceal hemorrhage, encephalopathy).
8.    Confirmed active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
9.    Subjects with alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
≥3 times the upper limit of normal (ULN) or total bilirubin ≥2 × ULN at Screening.
10.    Chronic renal insufficiency as defined by serum creatinine >2.5 mg/dL or requiring dialysis at Screening.
11.    Hemoglobin concentration <9 g/dL at Screening.
12.    Subjects treated with an IV or SC prostacyclin pathway agent (eg, epoprostenol, treprostinil, or iloprost) at any time prior to Baseline (use in vasoreactive testing is permitted).
13.    Subjects treated with an inhaled or oral prostacyclin pathway agent (iloprost, treprostinil, beraprost, or selexipag) that was stopped for a safety or tolerability issue.
    If a subject discontinued for other reasons, the subject is eligible if the subject has been off therapy and stable (ie, no change in WHO/NYHA FC or change in PAH-specific background oral therapy) for 90 days prior to Baseline.
14.    Subject has pulmonary veno-occlusive disease.
15.    Malignancy diagnosed and/or treated within 5 years prior to Screening, with the exception of localized non-metastatic basal cell or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix excised with curative intent.
16.    Subject tests positive for amphetamine, cocaine, methamphetamine, methylenedioxymethamphetamine or phencyclidine in urine drug screen performed at Screening, or has a recent history (6 months) of alcohol or drug abuse.
17.    Initiation of a cardio-pulmonary rehabilitation program based upon exercise within
90 days prior to Screening and/or planned during study participation.

18.    Prior participation in any study of ralinepag or participation in another interventional clinical study within 30 days prior to Screening.  Concurrent participation in registry or observational studies is allowed, as long as the subject can fulfill all other entry criteria and comply with all study procedures.
19.    Any reason that, in the opinion of the Investigator or Medical Monitor, precludes the subject from participating in the study (eg, any previous or intercurrent medical condition) that may increase the risk associated with study participation or that would confound study analysis or impair study participation or cooperation.
20.    Known hypersensitivity to ralinepag or any of the excipients.
21.    Life expectancy <12 months based on the Investigator’s opinion.
22.    Women who are pregnant, lactating or breast-feeding.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Charles Burger, M.D.

Contact us for the latest status

Contact information:

Inna Abrea B.S.

Abrea.Inna@mayo.edu

Rochester, Minn.

Mayo Clinic principal investigator

Hector Cajigas, M.D.

Contact us for the latest status

Contact information:

Pulmonary Clinical Research Unit

(800) 753-1606

PCRUE18@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available